<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00800540</url>
  </required_header>
  <id_info>
    <org_study_id>C-07-16</org_study_id>
    <secondary_id>2007-005936-99</secondary_id>
    <nct_id>NCT00800540</nct_id>
  </id_info>
  <brief_title>Circadian Ocular Perfusion Pressure and Ocular Blood Flow</brief_title>
  <official_title>Effects of Topical Hypotensive Drugs on Circadian Ocular Perfusion Pressure and Ocular Blood Flow in Patients With Open-Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to compare the short term effects of two intraocular pressure
      (IOP) lowering medications on ocular perfusion pressure (OPP), ocular blood flow, intraocular
      pressure, and blood pressure in patients with glaucoma. Ocular perfusion pressure (OPP) is
      defined as the difference between arterial blood pressure (diastolic and systolic) and
      intraocular pressure. The primary efficacy assessment is based on diastolic ocular perfusion
      pressure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in Overall Diastolic Ocular Perfusion Pressure at Week 6</measure>
    <time_frame>Week 0, Week 6 (period-based)</time_frame>
    <description>Diastolic ocular perfusion pressure (DOPP) is defined as the difference between diastolic arterial pressure and intraocular pressure. Diastolic arterial pressure was measured with a calibrated automated sphygmomanometer. Intraocular pressure was measured with a calibrated pneumatonometer. A lower DOPP indicates a lower optic blood supply, which can be a risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Circadian Diastolic Ocular Perfusion Pressure at Week 6</measure>
    <time_frame>Week 0, Week 6 (period-based)</time_frame>
    <description>Circadian diastolic ocular perfusion pressure (COPP) is defined as the variations in diastolic OPP during the day and night. Diastolic ocular perfusion pressure was calculated at 7 timepoints over a 24-hour period. Changes in the diastolic ocular perfusion pressure rhythm throughout the day (outside the normal range) may affect glaucoma progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Mean Flow Value in the Superotemporal Peripapillary Retina at Week 6</measure>
    <time_frame>Week 0, Week 6 (period-based)</time_frame>
    <description>Retinal perfusion assessments were made using Heidelberg Retinal Flowmetry (HRF). Assessments were made at 4 timepoints over a 12-hour period. Intensity of blood flow was measured in arbitrary units, with a higher number indicating an increased blood flow. An increase in ocular blood flow may reduce the risk of glaucoma progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Mean Flow Value in the Inverotemporal Peripapillary Retina at Week 6</measure>
    <time_frame>Week 0, Week 6 (period-based)</time_frame>
    <description>Retinal perfusion assessments were made using Heidelberg Retinal Flowmetry (HRF). Assessments were made at 4 timepoints over a 12-hour period. Intensity of blood flow was measured in arbitrary units, with a higher number indicating an increased blood flow. An increase in ocular blood flow may reduce the risk of glaucoma progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Intraocular Pressure (IOP) at Week 6</measure>
    <time_frame>Week 0, Week 6 (period-based)</time_frame>
    <description>Intraocular pressure (IOP) is defined as the fluid pressure inside the eye. Intraocular pressure was measured with a calibrated pneumatonometer at 7 time points over a 24-hour period. High IOP (outside the normal range) can be a risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Diastolic Blood Pressure at Week 6</measure>
    <time_frame>Week 0, Week 6 (period-based)</time_frame>
    <description>Blood pressure is defined as the pressure exerted by circulating blood upon the walls of the blood vessels, that is, arterial pressure of the systemic circulation of blood. Diastolic blood pressure refers to the minimum pressure, that is, the pressure between heartbeats. Diastolic glood pressure was measured at 7 timepoints in a 24-hour period using a calibrated sphygmomonometer. Higher blood pressure (outside the normal range) can be a risk factor for developing cardiovascular events, such as heart attack, stroke, or heart failure. Lower blood pressure (outside the normal range) can be a risk factor for dizziness or fainting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Systolic Blood Pressure at Week 6</measure>
    <time_frame>Week 0, Week 6 (period-based)</time_frame>
    <description>Blood pressure is defined as the pressure exerted by circulating blood upon the walls of the blood vessels, that is, arterial pressure of the systemic circulation of blood. Systolic blood pressure refers to the maximum pressure, that is, the pressure while the heart is beating, and was measured at 7 timepoints in a 24-hour period using a calibrated sphygmomonometer. Higher blood pressure (outside the normal range) can be a risk factor for developing cardiovascular events, such as heart attack, stroke, or heart failure. Lower blood pressure (outside the normal range) can be a risk factor for dizziness or fainting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Vascular Resistance in the Central Retinal Artery at Week 6</measure>
    <time_frame>Week 0, Week 6 (period-based)</time_frame>
    <description>Vascular resistance in the central retinal artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Vascular Resistance in the Ophthalmic Artery at 6 Weeks</measure>
    <time_frame>Week 0, Week 6 (period-based)</time_frame>
    <description>Vascular resistance in the ophthalmic artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in End Diastolic Velocity in the Ophthalmic Artery at Week 6</measure>
    <time_frame>Week 0, Week 6 (period-based)</time_frame>
    <description>End diastolic velocity in the ophthalmic artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Peak Systolic Velocity in the Ophthalmic Artery at Week 6</measure>
    <time_frame>Week 0, Week 6 (period-based)</time_frame>
    <description>Peak systolic velocity in the ophthalmic artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Peak Systolic Velocity in the Central Retinal Artery at Week 6</measure>
    <time_frame>Week 0, Week 6 (period-based)</time_frame>
    <description>Peak systolic velocity in the central retinal artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>AZARGA/COMBIGAN</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>AZARGA, followed by COMBIGAN, as randomized. Each fixed combination instilled in the study eye, one drop twice daily (9:00 and 21:00), for six weeks, with a 4-week washout period separating the two treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COMBIGAN/AZARGA</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>COMBIGAN, followed by AZARGA, as randomized. Each fixed combination instilled in the study eye, one drop twice daily (9:00 and 21:00), for six weeks, with a 4-week washout period separating the two treatment periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension</intervention_name>
    <description>Fixed combination ophthalmic suspension</description>
    <arm_group_label>AZARGA/COMBIGAN</arm_group_label>
    <arm_group_label>COMBIGAN/AZARGA</arm_group_label>
    <other_name>AZARGA™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution</intervention_name>
    <description>Fixed combination ophthalmic solution</description>
    <arm_group_label>AZARGA/COMBIGAN</arm_group_label>
    <arm_group_label>COMBIGAN/AZARGA</arm_group_label>
    <other_name>COMBIGAN®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sign Informed Consent.

          -  Diagnosis of open-angle glaucoma in at least one eye.

          -  Requires more than one IOP-lowering medication.

          -  IOP measurements at Screening, Safety, and Eligibility/Period 1 Baseline Visits as
             specified in protocol.

          -  Able to discontinue all IOP-lowering medication prior to Eligibility Visit and for 4
             weeks between treatment periods.

          -  Willing to complete all required study visits.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Female of child-bearing potential if pregnant, lactating, or not using highly
             effective birth control measures.

          -  Severe central visual field loss in either eye.

          -  Previous glaucoma surgery in the study eye.

          -  Intraocular surgery in the study eye within 3 months prior to the Screening Visit.

          -  Wears contact lenses.

          -  Allergy/hypersensitivity to study medication.

          -  Cannot safely discontinue use of glucocorticoid medication.

          -  Uses medication that could affect IOP or blood pressure.

          -  Recent use of high-dose aspirin.

          -  Bronchial asthma or severe chronic obstructive pulmonary disease.

          -  Diabetic retinopathy.

          -  Any abnormality preventing reliable tonometry.

          -  Any severe illness or condition unsuitable for the study, in the opinion of the
             investigator.

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Contact Alcon Call Center at 1-888-451-3937 For Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2008</study_first_submitted>
  <study_first_submitted_qc>December 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2008</study_first_posted>
  <results_first_submitted>January 31, 2013</results_first_submitted>
  <results_first_submitted_qc>March 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 22, 2013</results_first_posted>
  <last_update_submitted>March 20, 2013</last_update_submitted>
  <last_update_submitted_qc>March 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>ocular perfusion pressure</keyword>
  <keyword>ocular blood flow</keyword>
  <keyword>open angle glaucoma requiring more than one IOP-lowering medication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Brimonidine Tartrate, Timolol Maleate Drug Combination</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
    <mesh_term>Brinzolamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from and enrolled at one study center located in Greece.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>AZARGA/COMBIGAN</title>
          <description>AZARGA, followed by COMBIGAN, as randomized. Each fixed combination was used for 6 weeks, with a 4-week washout period separating the two treatment periods.</description>
        </group>
        <group group_id="P2">
          <title>COMBIGAN/AZARGA</title>
          <description>COMBIGAN, followed by AZARGA, as randomized. Each fixed combination was used for 6 weeks, with a 4-week washout period separating the two treatment periods.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period One: 6 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pt Decision Unrelated to Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout: 4 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2: 6 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This reporting group includes all enrolled participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Overall</title>
          <description>All enrolled</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.2" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Overall Diastolic Ocular Perfusion Pressure at Week 6</title>
        <description>Diastolic ocular perfusion pressure (DOPP) is defined as the difference between diastolic arterial pressure and intraocular pressure. Diastolic arterial pressure was measured with a calibrated automated sphygmomanometer. Intraocular pressure was measured with a calibrated pneumatonometer. A lower DOPP indicates a lower optic blood supply, which can be a risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).</description>
        <time_frame>Week 0, Week 6 (period-based)</time_frame>
        <population>This reporting group includes all patients who received study medication and completed the on-therapy follow-up study visit in both periods (ITT).</population>
        <group_list>
          <group group_id="O1">
            <title>AZARGA</title>
            <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
          </group>
          <group group_id="O2">
            <title>COMBIGAN</title>
            <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Overall Diastolic Ocular Perfusion Pressure at Week 6</title>
          <description>Diastolic ocular perfusion pressure (DOPP) is defined as the difference between diastolic arterial pressure and intraocular pressure. Diastolic arterial pressure was measured with a calibrated automated sphygmomanometer. Intraocular pressure was measured with a calibrated pneumatonometer. A lower DOPP indicates a lower optic blood supply, which can be a risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).</description>
          <population>This reporting group includes all patients who received study medication and completed the on-therapy follow-up study visit in both periods (ITT).</population>
          <units>mmHg (millimeters of mercury)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.780"/>
                    <measurement group_id="O2" value="0.8" spread="0.779"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Circadian Diastolic Ocular Perfusion Pressure at Week 6</title>
        <description>Circadian diastolic ocular perfusion pressure (COPP) is defined as the variations in diastolic OPP during the day and night. Diastolic ocular perfusion pressure was calculated at 7 timepoints over a 24-hour period. Changes in the diastolic ocular perfusion pressure rhythm throughout the day (outside the normal range) may affect glaucoma progression.</description>
        <time_frame>Week 0, Week 6 (period-based)</time_frame>
        <population>This reporting group includes all patients who received study medication and completed the on-therapy follow-up study visit in both periods (ITT).</population>
        <group_list>
          <group group_id="O1">
            <title>AZARGA</title>
            <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
          </group>
          <group group_id="O2">
            <title>COMBIGAN</title>
            <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Circadian Diastolic Ocular Perfusion Pressure at Week 6</title>
          <description>Circadian diastolic ocular perfusion pressure (COPP) is defined as the variations in diastolic OPP during the day and night. Diastolic ocular perfusion pressure was calculated at 7 timepoints over a 24-hour period. Changes in the diastolic ocular perfusion pressure rhythm throughout the day (outside the normal range) may affect glaucoma progression.</description>
          <population>This reporting group includes all patients who received study medication and completed the on-therapy follow-up study visit in both periods (ITT).</population>
          <units>mmHg (millimeters of mercury)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>9:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="1.282"/>
                    <measurement group_id="O2" value="6.5" spread="1.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="1.282"/>
                    <measurement group_id="O2" value="2.1" spread="1.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="1.282"/>
                    <measurement group_id="O2" value="3.9" spread="1.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="1.282"/>
                    <measurement group_id="O2" value="2.0" spread="1.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.282"/>
                    <measurement group_id="O2" value="-5.6" spread="1.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="1.282"/>
                    <measurement group_id="O2" value="-4.0" spread="1.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.296"/>
                    <measurement group_id="O2" value="0.9" spread="1.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Mean Flow Value in the Superotemporal Peripapillary Retina at Week 6</title>
        <description>Retinal perfusion assessments were made using Heidelberg Retinal Flowmetry (HRF). Assessments were made at 4 timepoints over a 12-hour period. Intensity of blood flow was measured in arbitrary units, with a higher number indicating an increased blood flow. An increase in ocular blood flow may reduce the risk of glaucoma progression.</description>
        <time_frame>Week 0, Week 6 (period-based)</time_frame>
        <population>This reporting group includes all patients who received study medication and completed the on-therapy follow-up study visit in both periods (ITT). The analysis is based on patient eye-matched image data received.</population>
        <group_list>
          <group group_id="O1">
            <title>AZARGA</title>
            <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
          </group>
          <group group_id="O2">
            <title>COMBIGAN</title>
            <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Mean Flow Value in the Superotemporal Peripapillary Retina at Week 6</title>
          <description>Retinal perfusion assessments were made using Heidelberg Retinal Flowmetry (HRF). Assessments were made at 4 timepoints over a 12-hour period. Intensity of blood flow was measured in arbitrary units, with a higher number indicating an increased blood flow. An increase in ocular blood flow may reduce the risk of glaucoma progression.</description>
          <population>This reporting group includes all patients who received study medication and completed the on-therapy follow-up study visit in both periods (ITT). The analysis is based on patient eye-matched image data received.</population>
          <units>Arbitrary Units</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>9:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-272.4" spread="146.294"/>
                    <measurement group_id="O2" value="-43.5" spread="146.586"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.1" spread="142.844"/>
                    <measurement group_id="O2" value="248.9" spread="144.917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.7" spread="144.914"/>
                    <measurement group_id="O2" value="-51.3" spread="142.844"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" spread="148.317"/>
                    <measurement group_id="O2" value="-33.2" spread="144.451"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Mean Flow Value in the Inverotemporal Peripapillary Retina at Week 6</title>
        <description>Retinal perfusion assessments were made using Heidelberg Retinal Flowmetry (HRF). Assessments were made at 4 timepoints over a 12-hour period. Intensity of blood flow was measured in arbitrary units, with a higher number indicating an increased blood flow. An increase in ocular blood flow may reduce the risk of glaucoma progression.</description>
        <time_frame>Week 0, Week 6 (period-based)</time_frame>
        <population>This reporting group includes all patients who received study medication and completed the on-therapy follow-up study visit in both periods (ITT). The analysis is based on patient eye-matched image data received.</population>
        <group_list>
          <group group_id="O1">
            <title>AZARGA</title>
            <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
          </group>
          <group group_id="O2">
            <title>COMBIGAN</title>
            <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Mean Flow Value in the Inverotemporal Peripapillary Retina at Week 6</title>
          <description>Retinal perfusion assessments were made using Heidelberg Retinal Flowmetry (HRF). Assessments were made at 4 timepoints over a 12-hour period. Intensity of blood flow was measured in arbitrary units, with a higher number indicating an increased blood flow. An increase in ocular blood flow may reduce the risk of glaucoma progression.</description>
          <population>This reporting group includes all patients who received study medication and completed the on-therapy follow-up study visit in both periods (ITT). The analysis is based on patient eye-matched image data received.</population>
          <units>Arbitrary Units</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>9:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" spread="92.064"/>
                    <measurement group_id="O2" value="-70.0" spread="89.642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.7" spread="89.642"/>
                    <measurement group_id="O2" value="-89.2" spread="95.324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-38.7" spread="88.363"/>
                    <measurement group_id="O2" value="-69.1" spread="92.610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182.3" spread="92.064"/>
                    <measurement group_id="O2" value="-91.0" spread="92.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Intraocular Pressure (IOP) at Week 6</title>
        <description>Intraocular pressure (IOP) is defined as the fluid pressure inside the eye. Intraocular pressure was measured with a calibrated pneumatonometer at 7 time points over a 24-hour period. High IOP (outside the normal range) can be a risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).</description>
        <time_frame>Week 0, Week 6 (period-based)</time_frame>
        <population>This reporting group includes all patients who received study medication and completed the on-therapy follow-up study visit in both periods (ITT).</population>
        <group_list>
          <group group_id="O1">
            <title>AZARGA</title>
            <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
          </group>
          <group group_id="O2">
            <title>COMBIGAN</title>
            <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Intraocular Pressure (IOP) at Week 6</title>
          <description>Intraocular pressure (IOP) is defined as the fluid pressure inside the eye. Intraocular pressure was measured with a calibrated pneumatonometer at 7 time points over a 24-hour period. High IOP (outside the normal range) can be a risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).</description>
          <population>This reporting group includes all patients who received study medication and completed the on-therapy follow-up study visit in both periods (ITT).</population>
          <units>mmHg (millimeters of mercury)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>9:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.3" spread="0.661"/>
                    <measurement group_id="O2" value="-6.5" spread="0.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.0" spread="0.661"/>
                    <measurement group_id="O2" value="-6.5" spread="0.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="0.661"/>
                    <measurement group_id="O2" value="-5.2" spread="0.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="0.661"/>
                    <measurement group_id="O2" value="-4.9" spread="0.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="0.661"/>
                    <measurement group_id="O2" value="-1.6" spread="0.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="0.661"/>
                    <measurement group_id="O2" value="-0.6" spread="0.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="0.668"/>
                    <measurement group_id="O2" value="-1.2" spread="0.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Diastolic Blood Pressure at Week 6</title>
        <description>Blood pressure is defined as the pressure exerted by circulating blood upon the walls of the blood vessels, that is, arterial pressure of the systemic circulation of blood. Diastolic blood pressure refers to the minimum pressure, that is, the pressure between heartbeats. Diastolic glood pressure was measured at 7 timepoints in a 24-hour period using a calibrated sphygmomonometer. Higher blood pressure (outside the normal range) can be a risk factor for developing cardiovascular events, such as heart attack, stroke, or heart failure. Lower blood pressure (outside the normal range) can be a risk factor for dizziness or fainting.</description>
        <time_frame>Week 0, Week 6 (period-based)</time_frame>
        <population>This reporting group includes all patients who received study medication and completed the on-therapy follow-up study visit in both periods (ITT).</population>
        <group_list>
          <group group_id="O1">
            <title>AZARGA</title>
            <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
          </group>
          <group group_id="O2">
            <title>COMBIGAN</title>
            <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Diastolic Blood Pressure at Week 6</title>
          <description>Blood pressure is defined as the pressure exerted by circulating blood upon the walls of the blood vessels, that is, arterial pressure of the systemic circulation of blood. Diastolic blood pressure refers to the minimum pressure, that is, the pressure between heartbeats. Diastolic glood pressure was measured at 7 timepoints in a 24-hour period using a calibrated sphygmomonometer. Higher blood pressure (outside the normal range) can be a risk factor for developing cardiovascular events, such as heart attack, stroke, or heart failure. Lower blood pressure (outside the normal range) can be a risk factor for dizziness or fainting.</description>
          <population>This reporting group includes all patients who received study medication and completed the on-therapy follow-up study visit in both periods (ITT).</population>
          <units>mmHg (millimeters of mercury)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>9:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="1.315"/>
                    <measurement group_id="O2" value="0.6" spread="1.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="1.315"/>
                    <measurement group_id="O2" value="-4.3" spread="1.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="1.315"/>
                    <measurement group_id="O2" value="-0.9" spread="1.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.315"/>
                    <measurement group_id="O2" value="-2.1" spread="1.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="1.315"/>
                    <measurement group_id="O2" value="-7.3" spread="1.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="1.315"/>
                    <measurement group_id="O2" value="-3.8" spread="1.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="1.334"/>
                    <measurement group_id="O2" value="-0.7" spread="1.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Systolic Blood Pressure at Week 6</title>
        <description>Blood pressure is defined as the pressure exerted by circulating blood upon the walls of the blood vessels, that is, arterial pressure of the systemic circulation of blood. Systolic blood pressure refers to the maximum pressure, that is, the pressure while the heart is beating, and was measured at 7 timepoints in a 24-hour period using a calibrated sphygmomonometer. Higher blood pressure (outside the normal range) can be a risk factor for developing cardiovascular events, such as heart attack, stroke, or heart failure. Lower blood pressure (outside the normal range) can be a risk factor for dizziness or fainting.</description>
        <time_frame>Week 0, Week 6 (period-based)</time_frame>
        <population>This reporting group includes all patients who received study medication and completed the on-therapy follow-up study visit in both periods (ITT).</population>
        <group_list>
          <group group_id="O1">
            <title>AZARGA</title>
            <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
          </group>
          <group group_id="O2">
            <title>COMBIGAN</title>
            <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Systolic Blood Pressure at Week 6</title>
          <description>Blood pressure is defined as the pressure exerted by circulating blood upon the walls of the blood vessels, that is, arterial pressure of the systemic circulation of blood. Systolic blood pressure refers to the maximum pressure, that is, the pressure while the heart is beating, and was measured at 7 timepoints in a 24-hour period using a calibrated sphygmomonometer. Higher blood pressure (outside the normal range) can be a risk factor for developing cardiovascular events, such as heart attack, stroke, or heart failure. Lower blood pressure (outside the normal range) can be a risk factor for dizziness or fainting.</description>
          <population>This reporting group includes all patients who received study medication and completed the on-therapy follow-up study visit in both periods (ITT).</population>
          <units>mmHg (millimeters of mercury)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>9:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="2.134"/>
                    <measurement group_id="O2" value="4.5" spread="2.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="2.134"/>
                    <measurement group_id="O2" value="-1.9" spread="2.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="2.134"/>
                    <measurement group_id="O2" value="-0.4" spread="2.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="2.134"/>
                    <measurement group_id="O2" value="-0.6" spread="2.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="2.134"/>
                    <measurement group_id="O2" value="-12.2" spread="2.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="2.134"/>
                    <measurement group_id="O2" value="-3.0" spread="2.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="2.165"/>
                    <measurement group_id="O2" value="3.0" spread="2.134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Vascular Resistance in the Central Retinal Artery at Week 6</title>
        <description>Vascular resistance in the central retinal artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.</description>
        <time_frame>Week 0, Week 6 (period-based)</time_frame>
        <population>This reporting group includes all patients who received study medication and completed the on-therapy follow-up study visit in both periods (ITT). The analysis is based on patient eye-matched image data received.</population>
        <group_list>
          <group group_id="O1">
            <title>AZARGA</title>
            <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
          </group>
          <group group_id="O2">
            <title>COMBIGAN</title>
            <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Vascular Resistance in the Central Retinal Artery at Week 6</title>
          <description>Vascular resistance in the central retinal artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.</description>
          <population>This reporting group includes all patients who received study medication and completed the on-therapy follow-up study visit in both periods (ITT). The analysis is based on patient eye-matched image data received.</population>
          <units>cm/s (centimeters per second)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>9:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="0.014"/>
                    <measurement group_id="O2" value="0.01" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.014"/>
                    <measurement group_id="O2" value="0.01" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.014"/>
                    <measurement group_id="O2" value="-0.00" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.014"/>
                    <measurement group_id="O2" value="0.02" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.014"/>
                    <measurement group_id="O2" value="-0.01" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.014"/>
                    <measurement group_id="O2" value="0.01" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.014"/>
                    <measurement group_id="O2" value="0.02" spread="0.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Vascular Resistance in the Ophthalmic Artery at 6 Weeks</title>
        <description>Vascular resistance in the ophthalmic artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.</description>
        <time_frame>Week 0, Week 6 (period-based)</time_frame>
        <population>This reporting group includes all patients who received study medication and completed the on-therapy follow-up study visit in both periods (ITT). The analysis is based on patient eye-matched image data received.</population>
        <group_list>
          <group group_id="O1">
            <title>AZARGA</title>
            <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
          </group>
          <group group_id="O2">
            <title>COMBIGAN</title>
            <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Vascular Resistance in the Ophthalmic Artery at 6 Weeks</title>
          <description>Vascular resistance in the ophthalmic artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.</description>
          <population>This reporting group includes all patients who received study medication and completed the on-therapy follow-up study visit in both periods (ITT). The analysis is based on patient eye-matched image data received.</population>
          <units>cm/s (centimeters per second)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>9:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.012"/>
                    <measurement group_id="O2" value="-0.01" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.012"/>
                    <measurement group_id="O2" value="0.02" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.012"/>
                    <measurement group_id="O2" value="0.01" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.012"/>
                    <measurement group_id="O2" value="0.01" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.012"/>
                    <measurement group_id="O2" value="0.02" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.012"/>
                    <measurement group_id="O2" value="0.03" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.012"/>
                    <measurement group_id="O2" value="0.03" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in End Diastolic Velocity in the Ophthalmic Artery at Week 6</title>
        <description>End diastolic velocity in the ophthalmic artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.</description>
        <time_frame>Week 0, Week 6 (period-based)</time_frame>
        <population>This reporting group includes all patients who received study medication and completed the on-therapy follow-up study visit in both periods (ITT). The analysis is based on patient eye-matched image data received.</population>
        <group_list>
          <group group_id="O1">
            <title>AZARGA</title>
            <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
          </group>
          <group group_id="O2">
            <title>COMBIGAN</title>
            <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in End Diastolic Velocity in the Ophthalmic Artery at Week 6</title>
          <description>End diastolic velocity in the ophthalmic artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.</description>
          <population>This reporting group includes all patients who received study medication and completed the on-therapy follow-up study visit in both periods (ITT). The analysis is based on patient eye-matched image data received.</population>
          <units>cm/s (centimeters per second)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>9:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="0.454"/>
                    <measurement group_id="O2" value="-0.8" spread="0.448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="0.459"/>
                    <measurement group_id="O2" value="-1.2" spread="0.460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.459"/>
                    <measurement group_id="O2" value="0.2" spread="0.466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.454"/>
                    <measurement group_id="O2" value="-0.8" spread="0.448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="0.466"/>
                    <measurement group_id="O2" value="-1.4" spread="0.454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="0.454"/>
                    <measurement group_id="O2" value="-0.6" spread="0.459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.466"/>
                    <measurement group_id="O2" value="-0.5" spread="0.448"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Peak Systolic Velocity in the Ophthalmic Artery at Week 6</title>
        <description>Peak systolic velocity in the ophthalmic artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.</description>
        <time_frame>Week 0, Week 6 (period-based)</time_frame>
        <population>This reporting group includes all patients who received study medication and completed the on-therapy follow-up study visit in both periods (ITT). The analysis is based on patient eye-matched image data received.</population>
        <group_list>
          <group group_id="O1">
            <title>AZARGA</title>
            <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
          </group>
          <group group_id="O2">
            <title>COMBIGAN</title>
            <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Peak Systolic Velocity in the Ophthalmic Artery at Week 6</title>
          <description>Peak systolic velocity in the ophthalmic artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.</description>
          <population>This reporting group includes all patients who received study medication and completed the on-therapy follow-up study visit in both periods (ITT). The analysis is based on patient eye-matched image data received.</population>
          <units>cm/s (centimeters per second)</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>9:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="1.237"/>
                    <measurement group_id="O2" value="-3.8" spread="1.221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.251"/>
                    <measurement group_id="O2" value="-1.4" spread="1.254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.251"/>
                    <measurement group_id="O2" value="1.3" spread="1.267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.237"/>
                    <measurement group_id="O2" value="-1.4" spread="1.221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="1.268"/>
                    <measurement group_id="O2" value="-3.1" spread="1.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.235"/>
                    <measurement group_id="O2" value="0.0" spread="1.250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.267"/>
                    <measurement group_id="O2" value="1.5" spread="1.221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Peak Systolic Velocity in the Central Retinal Artery at Week 6</title>
        <description>Peak systolic velocity in the central retinal artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.</description>
        <time_frame>Week 0, Week 6 (period-based)</time_frame>
        <population>This reporting group includes all patients who received study medication and completed the on-therapy follow-up study visit in both periods (ITT). The analysis is based on patient eye-matched image data received.</population>
        <group_list>
          <group group_id="O1">
            <title>AZARGA</title>
            <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
          </group>
          <group group_id="O2">
            <title>COMBIGAN</title>
            <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Peak Systolic Velocity in the Central Retinal Artery at Week 6</title>
          <description>Peak systolic velocity in the central retinal artery was assessed using Color Doppler Imaging (CDI). Assessments were made at 7 time points over a 24-hour period.</description>
          <population>This reporting group includes all patients who received study medication and completed the on-therapy follow-up study visit in both periods (ITT). The analysis is based on patient eye-matched image data received.</population>
          <units>cm/s (centimeters per second)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>9:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.571"/>
                    <measurement group_id="O2" value="0.7" spread="0.565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="0.577"/>
                    <measurement group_id="O2" value="0.3" spread="0.578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.577"/>
                    <measurement group_id="O2" value="0.6" spread="0.565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9:00 pm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="0.565"/>
                    <measurement group_id="O2" value="-0.5" spread="0.565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.577"/>
                    <measurement group_id="O2" value="-0.5" spread="0.565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.565"/>
                    <measurement group_id="O2" value="-1.1" spread="0.570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6:00 am</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.571"/>
                    <measurement group_id="O2" value="0.9" spread="0.565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected for the duration of the study.</time_frame>
      <desc>The safety population is defined as patients who received study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>AZARGA</title>
          <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
        </group>
        <group group_id="E2">
          <title>COMBIGAN</title>
          <description>One drop in the study eye, twice daily (9:00 and 21:00), for six weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <description>Recurrent Illness</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Global Medical Affairs</name_or_title>
      <organization>Alcon Research, Ltd.</organization>
      <phone>1-888-451-3937</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

